sTILs vary markedly across breast cancer subtypes and correlate with aggressive pathological features, particularly TNBC, high-grade, hormone receptor negativity, and high proliferative index. Incorporating standardized sTIL assessment into routine reporting may help identify tumors with active immune microenvironments.
Verma et al. (Mon,) studied this question.